Tenaya targets $60M offering after heart disease pipeline updatesnews2025-12-12T12:04:38+00:00December 12th, 2025|Endpoints News|
In a first, FDA approves a gene therapy from a nonprofitnews2025-12-10T16:02:33+00:00December 10th, 2025|Endpoints News|
#ASH25: Early in vivo CAR-T results like Kelonia’s elicit excitement across the fieldnews2025-12-09T16:04:26+00:00December 9th, 2025|Endpoints News|
EpilepsyGTx gets $33M to test epilepsy gene therapy in Phase 1/2anews2025-12-09T16:00:08+00:00December 9th, 2025|Endpoints News|
Cell and gene therapy benefits company Aradigm raises $20Mnews2025-12-09T12:00:26+00:00December 9th, 2025|Endpoints News|
FDA sets new, higher bar for CAR-T cancer treatments to prove superioritynews2025-12-08T19:57:56+00:00December 8th, 2025|Endpoints News|
#ASH25: AstraZeneca’s dual-targeting CAR-T sees similar responses in Western patients as in Chinanews2025-12-06T20:00:15+00:00December 6th, 2025|Endpoints News|
Bristol Myers expands Breyanzi approval to marginal zone lymphomanews2025-12-05T19:17:02+00:00December 5th, 2025|Endpoints News|
Nationwide Children’s SLC6A1 gene therapy shows early promisenews2025-12-04T13:00:54+00:00December 4th, 2025|Endpoints News|
With Phase 3 Duchenne success, Capricor plots path forward after FDA rejectionnews2025-12-03T16:36:07+00:00December 3rd, 2025|Endpoints News|
